Lorence Kim is a venture partner at Third Rock Ventures and currently serves as the interim chief operating officer at Flare Therapeutics and a board observer of Rheos Medicines.
Previously, Lorence was the chief financial officer of Moderna for six years, where he was responsible for raising $4.4 billion of capital for the company and deploying resources to discover and advance a pipeline of 24 development candidates across infectious disease, oncology, rare disease and autoimmune disease. Moderna raised, as of his departure, the three largest private financing rounds, the largest IPO and the largest follow-on offering in biotech history. Lorence joined Moderna after an investment banking career at Goldman Sachs for 14 years as a managing director and co-head of the U.S. biotechnology investment banking effort. There, his responsibilities included corporate finance and mergers and acquisitions for the biotechnology industry, with several billion in equity and equity-linked financings, and more than $55 billion in M&A transactions. Previously, Lorence was a member of the board of directors of Seres Therapeutics from 2014 to 2020.
Lorence holds an MBA in healthcare management as a Palmer Scholar from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania’s School of Medicine.